3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
40
Cisplatin
25
Fluorouracil
24
Paclitaxel
21
Oxaliplatin
16
Capecitabine
12
Leucovorin
10
Irinotecan
10
Docetaxel
10
Gemcitabine
8
Carboplatin
7
atezolizumab
6
Nivolumab
6
Bevacizumab
6
Trastuzumab
5
Ramucirumab
5
Radiotherapy
5
spartalizumab
4
Albumin-Bound Paclitaxel
4
zanidatamab
3
tisotumab vedotin
3
patritumab deruxtecan
3
lenvatinib
3
fludarabine
3
durvalumab
3
Radiation
3
Drug Therapy
3
Cyclophosphamide
3
130-nm albumin-bound paclitaxel
3
zimberelimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Neoplasms
×
Histamine H2 Antagonists
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled